

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number
WO 2004/065613 A2

- (51) International Patent Classification⁷: C12Q (74) Agents: WEICKMANN & WEICKMANN et al.; Postfach 860 820, 81635 München (EP).
- (21) International Application Number: PCT/EP2004/000265 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 15 January 2004 (15.01.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 03001058.1 17 January 2003 (17.01.2003) EP (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (for all designated States except US): MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. [DE/DE]; Hofgartenstr. 8, 80539 München (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): TUSCHL, Thomas [DE/US]; 504 East 63rd Street, #37 R, New York, NY 10021 (US). ACHSEL, Tilmann [DE/IT]; Corso del Popolo 6, I-00046 Grottaferrato (IT). LÜHRMANN, Reinhard [DE/DE]; Ewiges Tal 16b, 35041 Marburg-Michelbach (DE). MEYER, Jutta [DE/US]; 10 River Road Apt. 6B, Roosevelt Island, N.Y. 10044 (US).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/065613 A2

(54) Title: INDUCIBLE SMALL RNA EXPRESSION CONSTRUCTS FOR TARGETED GENE SILENCING

(57) Abstract: The invention relates to vectors for the inducible expression of RNA molecules in eukaryotic, particularly mammalian cells and transgenic animals.

- 1 -

Inducible small RNA expression constructs for targeted gene silencing

5

Description

The invention relates to vectors for the inducible expression of RNA molecules in eukaryotic, particularly mammalian cells and organisms.

10 Small double-stranded RNAs of approximately 20 to 30 base pairs have been shown to sequence-specifically direct mRNA degradation in mammalian cells (McManus and Sharp 2002). These small interfering RNAs (siRNAs) are preferentially 21 nucleotide (nt) long and paired such that they have a 19 base pair stem and 2-nt 3'-overhanging ends (Elbashir et al.
15 2001b; Elbashir et al. 2001a; Elbashir et al. 2001c; Elbashir et al. 2002). Such siRNA duplexes can be delivered into mammalian cells by microinjection, transfection or electroporation and may become a new class of therapeutic agents directed against genes that have been associated with pathogenesis, such as viral genes, by destroying their mRNAs and
20 thereby preventing their expression (Paddison and Hannon 2002; Tuschl and Borkhardt 2002). Double-stranded RNA longer than 30 base pairs can activate the interferon response causing unspecific translational arrest and apoptosis; these effects have not been observed with shorter dsRNAs (Bitko and Barik 2001; Elbashir et al. 2001b).

25

More recently a new class of genes was discovered that encode short dsRNA hairpin loops of about 25 to 30 basepairs in length that are processed to 21 to 23 nucleotide small RNAs (Lagos-Quintana et al. 2001; Lau et al. 2001; Lee and Ambros 2001; Lagos-Quintana et al. 2002). This
30 class was termed microRNAs. microRNAs function in the same pathway than siRNAs by associating with Argonaute proteins that are required for guiding target mRNA recognition (Hutvagner and Zamore 2002; Martinez et

- 2 -

al. 2002; Mourelatos et al. 2002). miRNAs cleave complementary target mRNAs in plants (Llave et al. 2002; Rhoades et al. 2002) but appear to repress mRNA translation rather than mRNA cleavage in animals (Hutvagner and Zamore 2002).

5

For gene targeting experiments, siRNAs were until recently introduced into cells via classic gene transfer methods such as liposome-mediated transfection, electroporation, or microinjection, which required chemical or enzymatic synthesis of siRNAs prior to its application, but siRNAs can also
10 be generated intracellularly by expression of siRNAs from plasmid DNA or retroviral, lentiviral or adenoviral constructs (Barton and Medzhitov 2002; Brummelkamp et al. 2002a; Brummelkamp et al. 2002b; Devroe and Silver 2002; McManus et al. 2002; Miyagishi and Taira 2002; Xia et al. 2002; Zeng et al. 2002). Intracellular transcription of small RNA molecules is
15 possible by cloning the siRNA templates into RNA polymerase III (pol III) transcription units, which normally encode the small nuclear RNA U6 or the human RNase P RNA H1. Two approaches have been developed for expressing siRNAs: (1) The sense and antisense strands constituting the siRNA duplex are transcribed by individual promoters (Lee et al. 2002; Miyagishi and Taira 2002) or (2) siRNAs are expressed as fold-back stem-loop structures that give rise to siRNAs after intracellular processing
20 (Brummelkamp et al. 2002b; Paul et al. 2002). The endogenous expression of siRNAs from introduced DNA templates is thought to overcome some limitations of exogenous siRNA delivery, in particular the transient loss-of-phenotype.
25

U6 and H1 RNA promoters are members of the type III of pol III promoters (Paule and White 2000). These promoters are unusual in that almost all their elements, with exception of the first transcribed nucleotide (+1
30 position), are located upstream of the transcribed region so that almost any inserted sequence shorter than 400 nt can be transcribed. They are therefore ideally suited for expression of the approximately 21-nt siRNAs or

- 3 -

the approximately 50-nt RNA stem-loops. The U6 promoter and the H1 promoter are different in size but contain the same conserved sequence elements or protein binding sites (Myslinski et al. 2001). The +1 nucleotide of the U6-like promoters is always guanosine, and always adenosine for H1. Interestingly, changing the +1 adenosine to U, C or G within H1 expressed stem-loop sequences did not seem to affect gene silencing, therefore suggesting that H1 promoters may be more flexible than U6 promoters for +1 sequence changes or may be able to initiate transcription at the first downstream purine nucleotide encoded by the template DNA (Brummelkamp et al. 2002b). RNA transcription is terminated when pol III encounters a run of 4 or 5 thymidines after incorporation of several uridine residues (Myslinski et al. 2001).

For practical applications, however, the considerable extra time involved in preparing and amplifying siRNA expression vectors and the transfection efficiency of plasmids relative to siRNAs must also be considered. Furthermore, targeting of essential genes causes arrest in cell growth or cell death within one to three days after delivery of siRNAs, thus making long-term silencing unnecessary if not impossible; the development of inducible siRNA expression systems may however provide an interesting alternative in such cases (Ohkawa and Taira 2000). However, when targeting non-essential proteins, stable knockdown cells may be of great value when studying inducible processes such as UV/irradiation damage response, host-pathogen interactions, or cell differentiation. In order to overcome the limitation of presently available targeting vectors we have explored the possibility of inserting regulatory protein binding sequences into the promoter region of pol III promoters.

A first aspect of the present invention is a recombinant vector for the inducible expression of a single-stranded or double-stranded RNA molecule in a eukaryotic, particularly mammalian, cell comprising at least one sequence coding for the RNA molecule operatively linked to an expression

- 4 -

control sequence comprising a polymerase III promoter and at least one regulatory protein binding site and optionally a transcription terminator. The polymerase III promoter and the regulatory protein binding site are located 5' to the coding sequence and the terminator is located 3' to the coding
5 sequence.

The vector may be any vector which is suitable for the transfection of eukaryotic cells, e.g. a DNA or an RNA vector. The vector may be a plasmid, for example a linear or a circular plasmid, a cosmid, a viral vector,
10 for example, an adenovirus, retrovirus, adeno-associated virus, vaccinia virus, lentivirus or an artificial chromosome. The vector may be an extrachromosomal vector or a vector which is capable of integrating into the genome of a host cell. Appropriate vectors are well known in the art and described in Sambrook et al. (1998), Molecular Cloning, A Laboratory
15 Manual, Cold Spring Harbor Press, and Ausubel et al. (1998), Current Protocols in Molecular Biology, John Wiley & Sons, for example.

The RNA molecule which is being expressed by the vector may be any RNA molecule having a length of from 15-500 nucleotides, preferably from
20 20-400 nucleotides. For example, the RNA may be a tRNA, an snRNA or a microRNA. Preferably, however, the RNA is an RNA molecule which is capable of RNA interference or an RNA molecule which is processed e.g. by cellular mechanisms to provide an RNA molecule which is capable of RNA interference. In an especially preferred embodiment, the RNA
25 molecule is a single-stranded RNA molecule having a length of from 30-100, more preferably 40-80 nucleotides. The single-stranded RNA molecule has a portion which is at least substantially complementary to a target transcript, i.e. a transcript, particularly an mRNA which is expressed in a target cell. Further, it is preferred that the single-stranded RNA molecule is
30 capable of forming a double-stranded hairpin structure. The hairpin structure preferably has a 3' overhang which may have a length from 1-5 nucleotides, more preferably from 1-3 nucleotides. In a further preferred

- 5 -

embodiment, the RNA molecule is a double-stranded RNA molecule which is comprised of 2 single-stranded RNA molecules which are individually expressed by one or several vectors and which are capable of forming a double-stranded RNA molecule. The double-stranded RNA molecule comprises an antisense strand which is at least substantially complementary to a target transcript and a sense strand which is at least substantially complementary to the anti-sense strand. Each strand has a length from preferably 19-30, more preferably from 19-25 nucleotides. The double-stranded RNA molecule has preferably at least one 3' overhang which has a length from 1-5 nucleotides, more preferably from 1-3 nucleotides.

The expression control sequence comprises a polymerase III promoter, more particularly a polymerase III promoter which is recognised in a predetermined host cell, e.g. a mammalian, particularly human, cell. Appropriate examples for polymerase III promoters are the H1 promoter, the U6 promoter, a tRNA promoter or other polymerase III promoters.

The expression control sequence may comprise one or several regulatory protein binding sites, e.g. 1, 2 or 3 regulatory protein-binding sites. Preferably at least one regulatory protein-binding site is located 5' to the TATA box of the polymerase III promoter. More preferably, at least one regulatory protein-binding site is located 5' and one regulatory protein-binding site is located 3' to the TATA box of the polymerase III promoter. The regulatory protein-binding site allows sequence specific binding of a regulatory protein and preferably has a length up to 25 nucleotides, more preferably up to 20 nucleotides.

The regulatory protein may be any protein which is capable of sequence-specific binding to a nucleic acid sequence, e.g. a repressor, a transcription factor, a nuclear receptor, etc. A preferred example of a regulatory protein is the tetracycline repressor, which is capable of sequence-specific binding

- 6 -

to a short nucleic acid sequence. The binding of the tetracycline repressor to its binding site within the expression control sequence leads to a repression of transcription. The tetracycline repressor binding may be abolished by adding tetracycline or a derivative thereof, e.g. doxycycline to the culture medium, resulting in an induction of RNA expression. The regulatory protein which recognizes the binding site is capable of being expressed in a cell which has been transfected with the vector of the invention. The expression of the regulatory protein may be constitutive or regulatable. The regulatory protein may be a protein endogenous to the transfected cell or a protein exogenous to the transfected cell, i.e. a protein coded by a nucleic acid sequence which has been inserted into the cell by recombinant means. For example, the nucleic acid encoding the regulatory protein may be located on the vector of the invention where it is operatively linked to an appropriate expression control sequence.

15

Preferably, the expression control sequence further comprises a transcription terminator. The transcription terminator may be a naturally occurring terminator, e.g. the U6 or the H1 terminator or a synthetic terminator. Preferably, the terminator starts with a sequence of several T nucleotides.

20

The sequence of the RNA molecule encoded by the vector of the present invention has to have a sufficient complementarity to a nucleic acid target molecule in order to mediate target-specific RNA interference. More particularly, a portion of the RNA molecule is substantially complementary to the target transcript.

25

The target RNA cleavage reaction guided by the RNA molecules encoded by the vector of the present invention is highly sequence-specific. However, not all positions of the RNA molecule contribute equally to target recognition. Mismatches, particularly at the 3'-terminus of the RNA molecule, more particularly at the residues 3' to the first 20 nt of the RNA

30

- 7 -

molecule are tolerated. Especially preferred are single-stranded RNA molecules or antisense strands of double-stranded RNA molecules having at the 5'-terminus at least 15 and preferably at least 20 nucleotides which are completely complementary to a predetermined target transcript or have
5 only one mismatch and optionally up to 15 nucleotides at the 3'-terminus which may contain 1 or several, e.g. 2, 3 or more mismatches.

A further aspect of the present invention relates to a method of mediating RNA interference in a cell or an organism comprising the steps:

10

(a) contacting the cell or organism with the vector of the invention under conditions wherein target-specific nucleic acid modifications mediated by the RNA molecule encoded by the vector are repressed and
and

15

(b) inducing a target-specific nucleic acid modification effected by the vector-encoded RNA molecule towards a target nucleic acid having a sequence portion substantially complementary to the RNA molecule.

20

Preferably the contacting step (a) comprises introducing the vector into a target cell, e.g. an isolated target cell, e.g. in cell culture, a unicellular microorganism or a target cell or a plurality of target cells within a multicellular organism. More preferably, the introducing step comprises a
25 carrier-mediated delivery, e.g. by liposomal carriers and/or by injection, or by delivery by electroporation, calcium phosphate precipitation, viral infection, etc. Further suitable delivery systems include Oligofectamine (Invitrogen) and Transit-TKO siRNA Transfection reagent (Mirus).

30

The method of the invention may be used for determining the function of a gene in a cell or an organism or even for modulating the function of a gene in a cell or an organism, being capable of mediating RNA interference.

- 8 -

The cell is preferably a eukaryotic cell or a cell line, e.g. a plant cell or an animal cell, such as a mammalian cell, e.g. an embryonic cell, a pluripotent stem cell, a tumor cell, e.g. a teratocarcinoma cell or a virus-infected cell. The organism is preferably a eukaryotic organism, e.g. a plant or an animal,
5 such as a mammal, particularly a human.

The target gene to which the RNA molecule is directed may be associated with a pathological condition. For example, the gene may be a pathogen-associated gene, e.g. a viral gene, a tumor-associated gene or an
10 autoimmune disease-associated gene. The target gene may also be a heterologous gene expressed in a recombinant cell or a genetically altered organism. By determining or modulating, particularly, inhibiting the function of such a gene valuable information and therapeutic benefits in the agricultural field or in the medicine or veterinary medicine field may be
15 obtained.

The present invention also allows a highly specific targeting of transcripts in a cell or in an organism, e.g. the targeting of individual transcript isoforms or transcript polymorphisms.

20

The vector may be administered as a pharmaceutical composition. The administration may be carried out by known methods, wherein a nucleic acid is introduced into a desired target cell in vitro or in vivo. Commonly used gene transfer techniques include calcium phosphate, DEAE-dextran,
25 electroporation and microinjection and viral methods (Graham, F.L. and van der Eb, A.J. (1973) Virol. 52, 456; McCutchan, J.H. and Pagano, J.S. (1968), J. Natl. Cancer Inst. 41, 351; Chu, G. et al (1987), Nucl. Acids Res. 15, 1311; Fraley, R. et al. (1980), J. Biol. Chem. 255, 10431; Capecchi, M.R. (1980), Cell 22, 479). A recent addition to this arsenal of techni-
30 ques for the introduction of nucleic acids into cells is the use of cationic liposomes (Felgner, P.L. et al. (1987), Proc. Natl. Acad. Sci USA 84, 7413). Commercially available cationic lipid formulations are e.g. Tfx 50

- 9 -

(Promega) or Lipofectamin2000 (Life Technologies). A further preferred method for the introduction of nucleic acids into a target organism, particularly into a mouse, is the high-pressure tail vein injection (Lewis, D.L. et al. (2002), Nat.Genet.29, 29; McCaffrey, A.P. et al. (2002), Nature
5 418, 38-39).

Thus, the invention also relates to a pharmaceutical composition containing as an active agent at least one vector as described above and pharmaceutically acceptable carriers, diluents and/or adjuvants. The
10 composition may be used for diagnostic and for therapeutic applications in human medicine or in veterinary medicine.

For diagnostic or therapeutic applications, the composition may be in form of a solution, e.g. an injectable solution, a cream, ointment, tablet, suspension or the like. The composition may be administered in any suitable way,
15 e.g. by injection, by oral, topical, nasal, rectal application etc. The carrier may be any suitable pharmaceutical carrier. Preferably, a carrier is used, which is capable of increasing the efficacy of the vector molecules to enter the target-cells. Suitable examples of such carriers are liposomes, particularly cationic liposomes. A further preferred administration method is injection.
20

A further preferred application of the RNAi method is a functional analysis of eukaryotic cells, or eukaryotic non-human organisms, preferably mammalian cells or organisms and most preferably human cells, e.g. cell lines
25 such as HeLa or 293 or rodents, e.g. rats and mice. By transfection with vector molecules which are homologous to a predetermined target gene encoding a suitable RNA molecule, a specific knockout phenotype can be obtained in a target cell, e.g. in cell culture or in a target organism. The
30 knockout phenotype may be regulated by induction or repression of the expression control sequence in the vector of the invention.

- 10 -

Further, the invention relates to a pharmaceutical composition for inhibiting the expression of a target transcript by RNA interference comprising as an active agent a vector as described above.

5 Furthermore, the invention relates to a method for the monitoring, prevention or treatment of a disease associated with overexpression of at least one target gene comprising administering a subject in need thereof a vector as described above.

10 Still a further subject matter of the present invention is a eukaryotic cell or a non-human transgenic animal which is transfected with a vector as described above. The cell may be a mammalian cell, e.g. a human cell. The non-human transgenic animal may be a mammal, e.g. a mouse, rat, hamster or monkey. The cell or animal may be transiently or stably
15 tranfected. A stable transfection is preferred.

Further the invention relates to a clonal cell population derived from a cell as described above, wherein the clonal cell population substantially consists of transfected cells and is free from non-transfected cells.

20

The eukaryotic cell or eukaryotic non-human organism exhibits an inducible target gene-specific knockout phenotype comprising an at least partially deficient expression of at least one endogeneous target gene RNA. It should be noted that the present invention allows the simultaneous or
25 subsequent transfection with several vectors coding for molecules of different sequences, which are either cognate to a different or the same target gene.

Gene-specific knockout phenotypes of cells or non-human organisms,
30 particularly of human cells or non-human mammals may be used in analytic procedures, e.g. in the functional and/or phenotypical analysis of complex physiological processes such as analysis of gene expression profiles and/or

- 11 -

proteomes. For example, one may prepare the knock-out phenotypes of human genes in cultured cells which are assumed to be regulators of alternative splicing processes. Among these genes are particularly the members of the SR splicing factor family, e.g. ASF/SF2, SC35, SRp20, SRp40 or SRp55. Further, the effect of SR proteins on the mRNA profiles of predetermined alternatively spliced genes such as CD44 may be analysed. Preferably the analysis is carried out by high-throughput methods using oligonucleotide based chips.

Using RNAi based knockout technologies, the expression of an endogenous target gene may be inhibited in a target cell or a target organism. The endogeneous gene may be complemented by an exogeneous target nucleic acid coding for the target protein or a variant or mutated form of the target protein, e.g. a gene or a cDNA, which may optionally be fused to a further nucleic acid sequence encoding a detectable peptide or polypeptide, e.g. an affinity tag, particularly a multiple affinity tag. Variants or mutated forms of the target gene differ from the endogeneous target gene in that they encode a gene product which differs from the endogeneous gene product on the amino acid level by substitutions, insertions and/or deletions of single or multiple amino acids. The variants or mutated forms may have the same biological activity as the endogeneous target gene. On the other hand, the variant or mutated target gene may also have a biological activity, which differs from the biological activity of the endogeneous target gene, e.g. a partially deleted activity, a completely deleted activity, an enhanced activity etc.

The complementation may be accomplished by coexpressing the polypeptide encoded by the exogeneous nucleic acid, e.g. a fusion protein comprising the target protein and the affinity tag and the RNA molecule for knocking out the endogeneous gene in the target cell. This coexpression may be accomplished by using a suitable expression vector expressing both the polypeptide encoded by the exogeneous nucleic acid, e.g. the tag-

- 12 -

modified target protein and the RNA molecule or alternatively by using a combination of expression vectors. Proteins and protein complexes which are synthesized de novo in the target cell will contain the exogenous gene product, e.g. the modified fusion protein. In order to avoid suppression of the exogenous gene product expression by the RNAi molecule, the nucleotide sequence encoding the exogenous nucleic acid may be altered on the DNA level (with or without causing mutations on the amino acid level) in the part of the sequence which is homologous to the RNA molecule. Alternatively, the endogenous target gene may be complemented by corresponding nucleotide sequences from other species, e.g. from mouse.

Preferred applications for the cell or organism of the invention is the analysis of gene expression profiles and/or proteomes. In an especially preferred embodiment an analysis of a variant or mutant form of one or several target proteins is carried out, wherein said variant or mutant forms are reintroduced into the cell or organism by an exogenous target nucleic acid as described above. The combination of knockout of an endogenous gene and rescue by using mutated, e.g. partially deleted exogenous target has advantages compared to the use of a knockout cell. Further, this method is particularly suitable for identifying functional domains of the target protein. In a further preferred embodiment a comparison, e.g. of gene expression profiles and/or proteomes and/or phenotypic characteristics of at least two cells or organisms is carried out. These organisms are selected from:

- (i) a control cell or control organism without target gene inhibition,
- (ii) a cell or organism with target gene inhibition and
- (iii) a cell or organism with target gene inhibition plus target gene complementation by an exogenous target nucleic acid.

The method and cell of the invention may also be used in a procedure for identifying and/or characterizing pharmacological agents, e.g. identifying

- 13 -

new pharmacological agents from a collection of test substances and/or characterizing mechanisms of action and/or side effects of known pharmacological agents.

5 Thus, the present invention also relates to a system for identifying and/or characterizing pharmacological agents acting on at least one target protein comprising:

- (a) a eukaryotic cell or a eukaryotic non-human organism capable of expressing at least one endogenous target gene coding for said target protein,
10
- (b) at least one vector as described above encoding an RNA molecule capable of inhibiting the expression of said at least one endogenous target gene by RNAi and
- (c) a test substance or a collection of test substances wherein pharmacological properties of said test substance or said collection are to
15 be identified and/or characterized.

Further, the system as described above preferably comprises:

- (d) at least one exogenous target nucleic acid coding for the target protein or a variant or mutated form of the target protein wherein
20 said exogenous target nucleic acid differs from the endogenous target gene on the nucleic acid level such that the expression of the exogenous target nucleic acid is substantially less inhibited by the RNA molecule than the expression of the endogenous target gene.

25

Furthermore, the RNA knockout complementation method may be used for preparative purposes, e.g. for the affinity purification of proteins or protein complexes from eukaryotic cells, particularly mammalian cells and more particularly human cells. In this embodiment of the invention, the exogenous target nucleic acid preferably codes for a target protein which is
30 fused to an affinity tag.

- 14 -

The preparative method may be employed for the purification of high molecular weight protein complexes which preferably have a mass of ≥ 150 kD and more preferably of ≥ 500 kD and which optionally may contain nucleic acids such as RNA. Specific examples are the heterotrimeric protein complex consisting of the 20 kD, 60 kD and 90 kD proteins of the U4/U6 snRNP particle, the splicing factor SF3b from the 17S U2 snRNP consisting of 5 proteins having molecular weights of 14, 49, 120, 145 and 155 kD and the 25S U4/U6/U5 tri-snRNP particle containing the U4, U5 and U6 snRNA molecules and about 30 proteins, which has a molecular weight of about 1.7 MD.

Further, the present invention is explained in more detail in the following Figures and Examples.

Figures

Figure 1. Sequences of the unmodified H1 promoter sequence including the GL2 hairpin sequence and the terminator sequences for polymerase III. The sequences are seamlessly joined to each other in the plasmid.

Figure 2. Illustration of the position of tetO binding sites inserted into the H1 promoter region. Transcription would begin immediately downstream of the 3'-most nucleotide shown. Preferably, the first transcribed nucleotide encodes a purine nucleotide.

Figure 3. Targeting of GL2 luciferase with hairpin expression vectors directed against GL2.

Figure 4. Targeting of GL2 luciferase with hairpin expression vectors directed against GL2. The H1 promoter hairpin constructs were transfected a day prior to reporter plasmid transfection to allow for expression of hairpin RNA prior to expression of reporter plasmids.

Figure 5. The nucleic acid sequence of the plasmid pH1-tetO4 used for inducible silencing of GL2 luciferase.

Examples

1. Materials and Methods

1.1 Plasmid construction

For plasmid construction of H1 promoter constructs, synthetic oligonucleotides were prepared and the hybridized and ligated to each other using T4 RNA ligase. The ligation product was then gelpurified and ligated into the sequencing vector pBluescript SK(-) (Stratagene) that was restricted with XhoI und BamHI and gel-purified to remove the excised fragment of the multiple cloning site.

- 16 -

To generate the H1-tetO4-insert, the following oligonucleotide strands were synthesized forming the sense orientation insert, 5'-TCGAAGATCTAATATTTGCATGTCGCTATGTGTTCTGGGAAATCACCAT A A A C G T G A A A T , 5' -

5 pCCCTATCAGTGATAGAGACTTATAAGTTCCTATCAGTGATAGAGAAT TCATTTTCGAAGTATTCCGCGTACGTTTTCGACG, and 5'-pTACGCGGAATACTTCGAAATTTTTTCTCGAGCTTCCTTCGGGAAGCTC TCCATATTTTTTG were combined with the following oligonucleotides forming the antisense orientation insert, 5'-

10 TATGGTGATTTCCCAGAACACATAGCGACATGCAAATATTAGATCT, 5'-pTACGCGGAATACTTCGAAATGAATTCTCTATCACTGATAGGGAACTTA TAAGTCTCTATCACTGATAGGGATTTTCACGTT, and 5'-pGATCCAAAAAATATGGAGAGCTTCCCGAAGGAAGCTCGAGAAAAAAT TTCGAAGTATTCCGCGTACGTCGAAACG. The XhoI site is no longer

15 existent upon ligation of the H1 promoter insert; the BamHI site remains intact. To insert a new hairpin sequence, the GL2 hairpin RNA sequence can be excised by digesting the plasmid with EcoRI and XhoI and ligating synthetic oligonucleotides, prehybridized to each other in that site.

20 1.2 Transfection and knockdown analysis

Per well of a 24 well plate, 1 μ g pGL2-SV40 firefly luciferase plasmid, 0.2 μ g pRL-TK seapansy luciferase plasmid, and 1 μ g H1-promoter-hairpin plasmid were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturers protocol. Doxycycline was used at a concentration of

25 0,2 μ g/ml in the medium. The medium containing transfection reagent was replaced 8 h after transfection with fresh medium. Cells were harvested by trypsination and lysed according to the dual luciferase kit instructions (Promega). Luciferase activity was monitored thereafter. If cells were first primed with H1-hairpin-plasmids, 2 μ g of plasmid DNA was used for

30 transfection. The medium containing transfection reagent was replaced 8 h after transfection with fresh medium, and transfection was repeated with the mixture of reporter and H1 plasmids as described.

- 17 -

2. Results

We constructed a total of five H1-derived promoters to drive transcription of a stem-loop RNA structure directed against the firefly luciferase GL2. All contain the same proximal sequence element, PSE, and the same
5 transcription terminator. The presumed transcription start is the first nucleotide of the stem-loop as listed below. The presumed termination is about two to four nucleotides within the first run of 6 thymidines of the terminator portion.

10 The region around the TATA box is variable: in H1, it is derived from the 'proper' H1 promoter. H1-tetO1, H1-tetO2, and H1-tetO2 each contain one binding site for the tetracycline repressor tetR. H1-tetO4 contains two tetR-binding sites.

15 To check the effect of these constructs in vivo, we transiently co-transfected the plasmids containing the H1 cassette with two reporter plasmids encoding the luciferase GL2 and the Renilla luciferase. The plasmid encoding the GL2 luciferase exhibits sequence homology to the expressed stem-loop; its expression should be suppressed by the stem-
20 loop. The plasmid encoding the seapansy (Renilla luciferase (pRL-TK), in contrast, exhibits no sequence homology and is not affected. Therefore, we calculated the ratio of the GL2 luciferase activity over the Renilla luciferase activity (the two enzymes can be distinguished as they use different substrates). The ratio obtained in the presence of an empty vector
25 instead of the H1 cassette was arbitrarily set to 1. Thus, a ratio of less than 1 indicates reduced expression of the GL2 luciferase and hence suppression of the gene. In this study, we used 'T-Rex' HeLa cells (Invitrogen) that constitutively express the tetR protein. We anticipated that the H1-tetO constructs are fully active only in the presence of the
30 tetracycline analogue doxycycline (dox) when the tetR protein does not bind its responsive element on the DNA. Note that the luciferase activities vary slightly in the presence or absence of doxycycline. Therefore, the

- 18 -

respective controls were independently set to 1. The luciferase activities were assayed two days after transfection to allow for full expression of the repressing stem-loop. After three days, the absolute activities were greatly diminished due to the transient nature of the transfection, but the ratios are
5 largely the same.

As shown in the figure 3, co-transfection of the H1 cassette reduces the GL2 activity to 40% of the control, irrespective of the presence or absence of doxycycline. Similar values are obtained for all H1-tetO constructs in the
10 presence of doxycycline, i.e., in the absence of tetR binding. In the absence of doxycycline, however, tetR can bind to the H1 promoter, and the constructs are less active: H1-tetO1 reduces the GL2 activity to 0,82, H1-tetO2 to 0,62, and H1-tetO3 to 0,58. Thus, the tet repressor appears to suppress transcription of the stem-loop more efficiently when bound
15 upstream of the TATA box as compared to downstream. The most drastic effect was observed for the construct that contains two tetR-binding sites: in the presence of doxycycline, this cassette represses GL2 luciferase expression as well as the other constructs. In the absence of doxycycline, however, the GL2 luciferase activity is apparently even increased, to 1,09.
20 The increase is probably within the experimental error and thus not significant, but GL2 activity is certainly not decreased. Therefore, the H1 promoter containing two tetR binding sites is inactive in the absence of doxycycline, and thus suitable for regulated suppression of a target gene.

25 In this experiment, none of the constructs reduced GL2 luciferase activity to less than 0,4, thus leaving a significant background of expressed luciferase. We believe that this background does not result from a general inability of the stem-loop to suppress the luciferase. Instead, we think that transcription of the stem-loop and maturation into a functional RISC
30 complex takes longer than the expression of active luciferase, thus leaving a significant background of luciferase expressed in the absence of silencing stem-loops. Additionally, the ratio of plasmids introduced into individual

- 19 -

cells may differ, i.e., one cell may obtain more of the H1 plasmid, and another less. Those cells that did not obtain enough of the repressing plasmid may have contributed to the background activity. In support of these notions, prolonged expression (up to three days after transfection)
5 led to a decreased 'background level' of GL2 activity: in this experiment, 0,26 to 0,33 (data not shown).

More importantly, transfection of the H1 cassettes only, followed by co-transfection of the two luciferases plus the H1 cassette one day later
10 increases the effect of the stem-loop expression (figure 4): in this set of experiments, the GL2 activities in the presence of doxycycline ranged between 20 and 30% of the control. As before, the H1-tetO4 construct has, in the absence of doxycycline, the same effect as H1 without tetR binding sites, whereas in the presence of doxycycline it is not significantly
15 active (0,94).

As silencing hairpin, a 23 base pair stem was selected, whereby the stem-loop of the sequence UUCG was connected to the 3' end of the antisense strand complementary to the GL2 target mRNA. The terminator signal was
20 positioned such that a 2 to 4 nucleotide oligoU 3'-overhang would be present on the transcribed hairpin. The loop sequence may also be exchanged with a six-nucleotide sequence of a restriction enzyme, allowing linearization of the plasmid prior to sequencing. Sequencing of hairpin
25 RNAs is sometimes cumbersome because of the stable hairpin structure through that can prevent the sequencing polymerase from reading through. Stems of 19 base pairs or greater (up to 29 base pairs) can be used in hairpin-mediated gene silencing.

3. Summary

30 In conclusion, the H1 cassette described here is capable of reducing expression of a target gene, and the variant H1-tetO4 allows for full control of the repression by addition of doxycycline to the medium. To

- 20 -

demonstrate that the construct can fully suppress a given target gene, it is preferred to establish permanent a cell line that is either insensitive to the transfection of GL2 luciferase or that does not express an endogenous protein. The (endogenous) protein can be switched on and off by
5 doxycycline when using the H1-tetO4 variant. That in particular would pave the way to switch off essential genes in a reliable and reproducible way.

The expression cassette, when integrated in the context of a selectable
10 plasmid backbone, can be stably integrated into mammalian cells. Mammalian cells also stably expressing tetR protein can then be induced to express the hairpin RNA. Essential genes can than be turned off in cells at any given time upon the addition of doxycycline to the tissue culture medium. Homogenous knockdown cell populations can be obtained
15 overcoming problems of inhomogeneous transfection. These cell lines will be of high value for proteomic or gene profile type analysis. An inducible promoter/hairpin system may also be used in transgenic animals to generate gene knockdowns (rather than gene knockouts) by feeding tetracycline or doxycycline. This may be useful for generating animal
20 models of disease that are caused by reduction of endogenous gene expression.

References

Barton G.M., and Medzhitov R. 2002. Retroviral delivery of small interfering RNA into primary cells. *Proc. Natl. Acad. Sci. USA* 99: 14943-14945.

5

Bitko V., and Barik S. 2001. Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. *BMC Microbiol.* 1: 34.

10

Brummelkamp T., Bernards R., and Agami R. 2002a. Stable suppression of tumorigenicity by virus-mediated RNA interference. *Cancer Cell* 2: 243.

Brummelkamp T.R., Bernards R., and Agami R. 2002b. A system for stable expression of short interfering RNAs in mammalian cells. *Science* 296: 550-553.

15

Devroe E., and Silver P.A. 2002. Retrovirus-delivered siRNA. *BMC Biotechnol* 2: 15.

20

Elbashir S.M., Lendeckel W., and Tuschl T. 2001a. RNA interference is mediated by 21 and 22 nt RNAs. *Genes & Dev.* 15: 188-200.

Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. 2001b. Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cell culture. *Nature* 411: 494-498.

25

Elbashir S.M., Martinez J., Patkaniowska A., Lendeckel W., and Tuschl T. 2001c. Functional anatomy of siRNAs for mediating efficient RNAi in *Drosophila melanogaster* embryo lysate. *EMBO J.* 20: 6877-6888.

30

- 22 -

- Elbashir S.M., Harborth J., Weber K., and Tuschl T. 2002. Analysis of gene function in somatic mammalian cells using small interfering RNAs. *Methods* 26: 199-213.
- 5 Hutvagner G., and Zamore P.D. 2002. A microRNA in a multiple-turnover RNAi enzyme complex. *Science* 1: 1.
- Lagos-Quintana M., Rauhut R., Lendeckel W., and Tuschl T. 2001. Identification of novel genes coding for small expressed RNAs. *Science*
10 294: 853-858.
- Lagos-Quintana M., Rauhut R., Yalcin A., Meyer J., Lendeckel W., and Tuschl T. 2002. Identification of tissue-specific microRNAs from mouse. *Curr. Biol.* 12: 735-739.
- 15 Lau N.C., Lim L.P., Weinstein E.G., and Bartel D.P. 2001. An abundant class of tiny RNAs with probable regulatory roles in *Caenorhabditis elegans*. *Science* 294: 858-862.
- 20 Lee N.S., Dohjima T., Bauer G., Li H., Li M.J., Ehsani A., Salvaterra P., and Rossi J. 2002. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. *Nat. Biotech.* 20: 500-505.
- Lee R.C., and Ambros V. 2001. An extensive class of small RNAs in *Caenorhabditis elegans*. *Science* 294: 862-864.
25
- Llave C., Xie Z., Kasschau K.D., and Carrington J.C. 2002. Cleavage of Scarecrow-like mRNA targets directed by a class of *Arabidopsis* miRNA. *Science* 297: 2053-2056.

30

- 23 -

Martinez J., Patkaniowska A., Urlaub H., Lührmann R., and Tuschl T. 2002. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. *Cell* 110: 563-574.

- 5 McManus M.T., and Sharp P.A. 2002. Gene silencing in mammals by small interfering RNAs. *Nat. Rev. Genet.* 3: 737-747.

McManus M.T., Petersen C.P., Haines B.B., Chen J., and Sharp P.A. 2002. Gene silencing using micro-RNA designed hairpins. *RNA* 8: 842-850.

10

Miyagishi M., and Taira K. 2002. U6 promoter driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. *Nat. Biotech.* 20: 497-500.

- 15 Mourelatos Z., Dostie J., Paushkin S., Sharma A., Charroux B., Abel L., Rappsilber J., Mann M., and Dreyfuss G. 2002. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. *Genes & Dev.* 16: 720-728.

- 20 Myslinski E., Amé J.-C., Krol A., and Carbon P. 2001. An unusually compact external promoter for RNA polymerase III transcription of the human H1 RNA gene. *Nucleic Acids Res.* 29: 2502-2509.

- 25 Ohkawa J., and Taira K. 2000. Control of the functional activity of an antisense RNA by a tetracycline-responsive derivative of the human U6 snRNA promoter. *Hum. Gene Ther.* 11: 577-585.

Paddison P.J., and Hannon G.J. 2002. RNA interference: the new somatic cell genetics? *Cancer Cell* 2: 17-23.

30

- 24 -

Paul C.P., Good P.D., Winer I., and Engelke D.R. 2002. Effective expression of small interfering RNA in human cells. *Nat. Biotech.* 20: 505-508.

- 5 Paule M.R., and White R.J. 2000. Transcription by RNA polymerase I and III. *Nucleic Acids Res.* 28: 1283-1298.

Rhoades M., Reinhart B., Lim L., Burge C., Bartel B., and Bartel D. 2002. Prediction of plant microRNA targets. *Cell* 110: 513.

10

Tuschl T., and Borkhardt A. 2002. Small interfering RNAs - a revolutionary tool for analysis of gene function and gene therapy. *Mol. Intervent.* 2: 42-51.

- 15 Xia H., Mao Q., Paulson H.L., and Davidson B.L. 2002. siRNA-mediated gene silencing in vitro and in vivo. *Nat. Biotech.* 20: 1006-1010.

Zeng Y., Wagner E.J., and Cullen B.R. 2002. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed
20 in human cells. *Mol. Cell* 9: 1327-1333.

- 25 -

Claims

1. A recombinant vector for the regulatable expression of a single-stranded or double-stranded RNA molecule in a eukaryotic cell comprising at least one sequence coding for the RNA molecule operatively linked to an expression control sequence comprising a polymerase III promoter and at least one regulatory protein-binding site.
2. The vector of claim 1 wherein the encoded RNA molecule is capable of RNA interference or is processed to provide an RNA molecule capable of RNA interference.
3. The vector of claims 1 or 2 wherein the RNA molecule is single-stranded.
4. The vector of claim 3 wherein the RNA molecule has a length of from 30-100 nucleotides.
5. The vector of claim 3 or 4 wherein the RNA molecule has a portion which is at least a portion which is at least substantially complementary to a target transcript.
6. The vector of any one of claims 3-5 wherein the RNA molecule is capable of forming a hairpin structure.
7. The vector of claim 6 wherein the hairpin structure has a 3' overhang.
8. The vector of claims 1 or 2 wherein the RNA molecule is double-stranded.

- 26 -

9. The vector of any one of claims 1-8 wherein the polymerase III promoter is an H1 promoter.
10. The vector of any one of claims 1-9 wherein the expression control
5 sequence comprises several regulatory protein-binding sites.
11. The vector of any one of claims 1-10 wherein at least one regulatory protein-binding site is located 5' to the TATA box of the promoter.
- 10 12. The vector of any one of the claims 1-11 wherein the regulatory protein-binding site is a binding site for the tetracycline repressor.
13. The vector of any one of claims 1-12 wherein the expression control sequence further comprises a transcription terminator.
15
14. The vector of any one of claims 1-13 for the inhibition of target gene expression in vitro.
15. The vector of any one of claims 1-13 for the inhibition of target
20 gene expression in vivo.
16. A pharmaceutical composition comprising at least one vector RNA molecule of any one of claims 1-15 as an active ingredient and pharmaceutically acceptable carriers, diluents and/or adjuvants.
25
17. The composition of claim 16 which is a cationic liposomal or lipid formulation.
18. The composition of claims 16 or 17 for diagnostic applications.
30
19. The composition of claim 18 for the monitoring of diseases associated with overexpression of at least one target manuscript.

- 27 -

20. The composition of claims 16 or 17 for therapeutic applications.
21. The composition of claim 20 for the prevention or treatment of diseases associated with overexpression of at least one target
5 manuscript.
22. The composition of claims 19 or 21 wherein the diseases are selected from tumour diseases, inflammatory diseases, infectious diseases, e.g. viral infections, degenerative diseases and
10 autoimmune diseases.
23. A eukaryotic cell which is transfected with a vector of any one of claims 1-15.
- 15 24. The cell of claim 23 which is a mammalian cell.
25. The cell of claim 24 which is a human cell.
26. The cell of any one of claims 23-24 which is stably transfected.
20
27. A clonal cell population derived from a cell of any one of claims 23-26.
28. The cell population of claim 27 consisting of transfected cells.
25
29. A non-human transgenic animal which is transfected with a vector of any one of claims 1-15.
30. The non-human animal of claim 29 which is a mammal.

-1/6-

Fig 1

H1 promoter 5'AATATTTGCATGTCGCTAIGIGTTCTGGGAAATCACCATAAACGTGAAATGTCCTTTGGATTG
GGAATCTTATAAGTTCTGTATGAGACCACTCGAATTC
GL2 hairpin 5' ATTCGAAGTATTCCGCGTACGTTTCGACGTACGCGGAATACTTCGAAA
terminator 5' TTTTICTCGAGCTTCCITCGGGAAGCTCTCCATATTTTTTGGATCC


-2/6-

Fig 2

H1 PSE ... TGTCTTTGGATTGGGAATCTTATAAGTTCTGTATGAGACCACTCGAATTC ... GL2 ...
tetO1 PSE ... TGTCTTTGGATTGGGAATCTTATAAGTTCTGTATGAGACCACTCGAATTC ... GL2 ...
tetO2 PSE ... TGTCTTTGGATTGGGAATCTTATAAGTTCTGTATGAGACCACTCGAATTC ... GL2 ...
tetO3 PSE ... TGTCTTTGGATTGGGAATCTTATAAGTTCTGTATGAGACCACTCGAATTC ... GL2 ...
tetO4 PSE ... TGTCTTTGGATTGGGAATCTTATAAGTTCTGTATGAGACCACTCGAATTC ... GL2 ...
 (green: TATA-box; red: tetR-binding site).


-3/6-

Fig 3



-4/6-

Fig 4



-5/6-

Fig 5

LOCUS
 DEFINITION pH1-TetO4, dereived from pBluescript SK(-)
 SOURCE T. Achsel, J. Meyer, T. Tuschl, MPI f. biophys. Chem, Goettingen, Germany
 ORGANISM unknown
 FEATURES
 misc_feature 749..752
 /note=""
 /standard_name="TATA-box"
 misc_feature order(728..746,756..774)
 /note=""
 /standard_name="tetO2 site"
 misc_feature 679..778
 /note=""
 /standard_name="H1 promoter"
 misc_feature order(779..826,826..828)
 /note=""
 /standard_name="GL2 hairpin RNA"
 misc_feature 668..673
 /note=""
 /standard_name="inactivated XhoI site"
 terminator 828..868
 /note=""
 /standard_name="terminator"
 BASE COUNT 749 a 784 c 753 g 822 t
 ORIGIN
 1 CACCTGACGC GCCCTGTAGC GCGCATTAA GCGCGGCGGG TGTGGTGGTT ACGCGCAGCG
 61 TGACCGCTAC ACTTGCCAGC GCCCTAGCGC CCGCTCCTTT CGCTTTCCTT CCTTCCTTTC
 121 TCGCCACGTT CGCCGGCTTT CCCCGTCAAG CTCTAAATCG GGGGCTCCCT TTAGGGTTC
 181 GATTTAGTGC TTTACGGCAC CTCGACCCCA AAAAAGTTGA TTAGGGTGAT GGTTCACGTA
 241 GTGGGCCATC GCCCTGATAG ACGGTTTTTC GCCCTTTGAC GTTGGAGTCC ACGTTCTTTA
 301 ATAGTGGACT CTTGTTCCAA ACTGGAACAA CACTCAACCC TATCTCGGTC TATTCTTTTG
 361 ATTTATAAGG GATTTTGCCG ATTTCCGCCCT ATTGGTTAAA AAATGAGCTG ATTTAACAAA
 421 AATTTAACGC GAATTTTAAAC AAAATATTAA CGCTTACAAT TTCCATTGCG CATTACAGGT
 481 GCGCAACTGT TGGGAAGGGC GATCGGTGCG GGCCTCTTCG CTATTACGCC AGCTGGCGAA
 541 AGGGGGATGT GCTGCAAGGC GATTAAAGTTG GGTAAACGCC GGGTTTTCCC AGTCACGACG
 601 TTGTAAAACG ACGGCCAGTG AATTGTAATA CGACTACTA TAGGGCGAAT GGGGTACCGG
 661 GCGCCCTCCT GAAGACTTAA TATTGCTATG TCGCTATGTG TTCTGGGAAA TCACCATAAA
 721 CGTGAAATCC CTATCAGTGA TAGAGACTTA TAAGTCCCT ATCAGTGATA GAGAATTCAT
 781 TTCGAAGTAT TCCGCGTACG TTTTCGACGTA CCGCGGAATAC TTCGAAATTT TTTCTCGAGC
 841 TTCTTTCGGG AAGCTCTCCA TATTTTGTG ATCCACTAGT TCTAGAGCGG CCGCCACCGC
 901 GGTGGAGCTC CAGCTTTTGT TCCCTTTAGT GAGGGTTAAT TTCGAGCTTG GCGTAATCAT
 961 GGTCATAGCT GTTTCCTGTG TGAATTTGTT ATCCGCTCAC AATTCCACAC AACATACGAG
 1021 CCGGAAGCAT AAAGTGTAATA GCCTGGGGTG CCTAATGAGT GAGCTAACTC ACATTAATTG
 1081 CGTTGCGCTC ACTGCCCGCT TTCCAGTCGG GAAACCTGTC GTGCCAGCTG CATTAAATGA
 1141 TCGGCCAACG CGCGGGGAGA GGCGGTTTGC GTATTGGGCG CTCTTCGCTC TCCTCGCTCA
 1201 CTGACTCGCT GCGCTCGGTC GTTCGGCTGC GCGGAGCGGT ATCAGCTCAC TCAAAGGCGG
 1261 TAATACGGTT ATCCACAGAA TCAGCGGATA ACGCAGGAAA GAACATGTGA GCAAAAGGCC
 1321 AGCAAAAGGC CAGGAACCGT AAAAAGGCCG CGTTGCTGGC GTTTTTCCTT AGGCTCCGCC
 1381 CCCCTGACGA GCATCACAAA AATCGACGCT CAAGTCAGAG GTGGCGAAAC CCGACAGGAC
 1441 TATAAAGATA CCAGGCGTTT CCCCTGGGAA GCTCCCTCGT GCGCTCTCCT GTTCCGACCC
 1501 TGCCGCTTAC CGGATACCTG TCCGCTTTTC TCCCTTCGGG AAGCGTGGCG CTTTCTCATA
 1561 GCTCACGCTG TAGGTATCTC AGTTCCGTTG AGGTCGTTTC CTCCAAGCTG GGCTGTGTGC
 1621 ACGAACCCCG CGTTCAGCCC GACCGCTGCG CCTTATCCGG TAACTATCGT CTTGAGTCCA
 1681 ACCCGGTAAG ACACGACTTA TCGCCACTGG CAGCAGCCAC TGGTAACAGG ATTAGCAGAG
 1741 CGAGGTATGT AGCGGGTGCT ACAGAGTTCT TGAAGTGGTG GCCTAACTAC GGCTACACTA
 1801 GAAGGACAGT ATTTGGTATC TGCCTCTGCG TGAAGCCAGT TACCTTCGGA AAAAGAGTTG
 1861 GTAGCTCTTG ATCCGGCAAA CAAACCAACG CTGGTAGCGG TGGTTTTTTT GTTTGCAAGC
 1921 AGCAGATTAC GCGCAGAAAA AAAGGATCTC AAGAAGATCC TTTGATCTTT TCTACGGGGT
 1981 CTGACGCTCA GTGGAACGAA AACTCACGTT AAGGGATTTT GGTCAATGAG TTATCAAAAA
 2041 GGATCTTCAC CTAGATCCTT TTAATATAAA AATGAAGTTT TAAATCAATC TAAAGTATAT
 2101 ATGAGTAAAC TTGGTCTGAC AGTTACCAAT GCTTAATCAG TGAGGCACCT ATCTCAGCGA
 2161 TCTGTCTATT TCGTTCATCC ATAGTTGCTT GACTCCCGGT CGTGTAGATA ACTACGATAC
 2221 GGGAGGGCTT ACCATCTGGC CCCAGTGCTG CAATGATACC GCGAGACCCA CGCTCACCGG
 2281 CTCCAGATTT ATCAGCAATA AACCAGCCAG CCGGAAGGGC CGAGCGCAGA GTTGGTCTCG
 2341 CAACCTTATC CGCCTCCATC CAGTCTATTA ATTGTTGCCG GGAAGCTAGA GTAAGTAGTT
 2401 CGCCAGTTAA TAGTTTGCAG AACGTTGTTG CCATTGCTAC AGGCATCGTG GTGTACGCT

-6/6-

Fig 6

```
2461 CGTCGTTTGG TATGGCTTCA TTCAGCTCCG GTTCCCAACG ATCAAGGCGA GTTACATGAT
2521 CCCCATGTT GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT GTCAGAAGTA
2581 AGTTGGCCGC AGTGTTATCA CTCATGGTTA TGGCAGCACT GCATAATTCT CTTACTGTCA
2641 TGCCATCCGT AAGATGCTTT TCTGTGACTG GTGAGTACTC AACCAAGTCA TTCTGAGAAT
2701 AGTGTATGCG GCGACCGAGT TGCTCTTGCC CGGCGTCAAT ACGGGATAAT ACCGCGCCAC
2761 ATAGCAGAAC TTTAAAAGTG CTCATCATTG GAAAACGTTT TTCGGGGCGA AAACCTCTCAA
2821 GGATCTTACC GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGCACCC AACTGATCTT
2881 CAGCATCTTT TACTTTCACC AGCGTTTCTG GGTGAGCAAA AACAGGAAGG CAAAATGCCG
2941 CAAAAAAGGG AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC CTTTTTCAAT
3001 ATTATTGAAG CATTATCAG GGTTATTGTC TCAIGAGCGG ATACATATTT GAATGTATTT
3061 AGAAAAATAA ACAAATAGGG GTTCCGCGCA CATTTCCCCG AAAAGTGC
```

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number
WO 2004/065613 A3

(51) International Patent Classification⁷: C12N 15/11

(21) International Application Number:
PCT/EP2004/000265

(22) International Filing Date: 15 January 2004 (15.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03001058.1 17 January 2003 (17.01.2003) EP

(71) Applicant (for all designated States except US): MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. [DE/DE]; Hofgartenstr. 8, 80539 München (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): TUSCHL, Thomas [DE/US]; 504 East 63rd Street, #37 R, New York, NY 10021 (US). ACHSEL, Tilmann [DE/IT]; Corso del Popolo 6, I-00046 Grottaferrato (IT). LÜHRMANN, Reinhard [DE/DE]; Ewiges Tal 16b, 35041 Marburg-Michelbach (DE). MEYER, Jutta [DE/US]; 10 River Road Apt. 6B, Roosevelt Island, N.Y. 10044 (US).

(74) Agents: WEICKMANN & WEICKMANN et al.; Postfach 860 820, 81635 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
7 October 2004

[Continued on next page]

(54) Title: INDUCIBLE SMALL INTERFERING RNA (SIRNA) EXPRESSION CONSTRUCTS FOR TARGETED GENE SILENCING



(57) Abstract: The invention relates to vectors for the inducible expression of RNA molecules in eukaryotic, particularly mammalian cells and transgenic animals.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/000265

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/11

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | <p>OHKAWA J ET AL: "Control of the functional activity of an antisense RNA by a tetracycline-responsive derivative of the human U6 snRNA promoter." HUMAN GENE THERAPY. 1 MAR 2000, vol. 11, no. 4, 1 March 2000 (2000-03-01), pages 577-585, XP000926522 ISSN: 1043-0342 abstract page 584, column 1, last paragraph</p> <p style="text-align: center;">----- -/--</p> | 1-30 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

3 August 2004

Date of mailing of the international search report

18/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Chakravarty, A

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/000265

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|---|-----------------------|
| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| X | <p>LUUKKONEN B G ET AL: "Construction of an in vivo-regulated U6 snRNA transcription unit as a tool to study U6 function." RNA (NEW YORK, N.Y.) FEB 1998, vol. 4, no. 2, February 1998 (1998-02), pages 231-238, XP002291073 ISSN: 1355-8382 abstract</p> | 1-30 |
| E | <p>WO 2004/056964 A (ETEMAD-MOGHADAM BIJAN ; GENPATH PHARMACEUTICALS INC (US); HEYER JOERG) 8 July 2004 (2004-07-08) claims</p> | 1-30 |
| P,X | <p>XIA XU GANG ET AL: "An enhanced U6 promoter for synthesis of short hairpin RNA." NUCLEIC ACIDS RESEARCH. 1 SEP 2003, vol. 31, no. 17, 1 September 2003 (2003-09-01), page e100, XP002291074 ISSN: 1362-4962 abstract</p> | 1-30 |
| P,X | <p>MATSUKURA SHIRO ET AL: "Establishment of conditional vectors for hairpin siRNA knockdowns." NUCLEIC ACIDS RESEARCH. 1 AUG 2003, vol. 31, no. 15, 1 August 2003 (2003-08-01), page e77, XP002291075 ISSN: 1362-4962 abstract</p> | 1-30 |
| P,X | <p>CZAUDEIRA FRANK ET AL: "Inducible shRNA expression for application in a prostate cancer mouse model." NUCLEIC ACIDS RESEARCH. 1 NOV 2003, vol. 31, no. 21, 1 November 2003 (2003-11-01), page e127, XP002291076 ISSN: 1362-4962 abstract</p> | 1-30 |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP2004/000265

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:

a. type of material

☒

a sequence listing

☐

table(s) related to the sequence listing

b. format of material

☒

in written format

☒

in computer readable form

c. time of filing/furnishing

☐

contained in the international application as filed

☐

filed together with the international application in computer readable form

☒

furnished subsequently to this Authority for the purpose of search

2. ☒ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/000265

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| WO 2004056964 A | 08-07-2004 | WO 2004056964 A2 | 08-07-2004 |